America Great Health (AAGH) financial statements (2022 and earlier)
Company profile
| Business Address |
1609 W VALLEY BLVD UNIT 338A ALHAMBRA, CA 91803 |
| State of Incorp. | CA |
| Fiscal Year End | June 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 TTM | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 206 | 396 | 0 | 0 | 0 | 4 | ||
| Cash and cash equivalents | 206 | 396 | 0 | 0 | 0 | 4 | ||
| Receivables | 76 | 61 | 3 | 0 | 0 | |||
| Inventory, net of allowances, customer advances and progress billings | 72 | 8 | 1 | |||||
| Inventory | 72 | 8 | 1 | |||||
| Prepaid expense | 100 | |||||||
| Advances on inventory purchases | 18 | 18 | ||||||
| Other undisclosed current assets | 1 | 1 | ||||||
| Total current assets: | 472 | 483 | 4 | 0 | 0 | 4 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 102 | 127 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 30 | 13 | ||||||
| Long-term investments and receivables | 13 | |||||||
| Long-term investments | 13 | |||||||
| Total noncurrent assets: | 131 | 140 | 13 | |||||
| TOTAL ASSETS: | 604 | 623 | 4 | 0 | 13 | 4 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 1,752 | 57 | 49 | 39 | 20 | 8 | ||
| Accrued liabilities | 8 | |||||||
| Taxes payable | 1 | 2 | 1 | |||||
| Other undisclosed accounts payable and accrued liabilities | 1,752 | 56 | 48 | 38 | 20 | |||
| Due to related parties | 225 | 324 | 168 | 128 | 101 | 44 | ||
| Other undisclosed current liabilities | 52 | 51 | 2 | 1 | ||||
| Total current liabilities: | 2,029 | 432 | 219 | 168 | 121 | 52 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 1,169 | 658 | ||||||
| Long-term debt, excluding current maturities | 1,120 | 582 | ||||||
| Operating lease, liability | 50 | 76 | ✕ | ✕ | ✕ | |||
| Other undisclosed noncurrent liabilities | (50) | (76) | ||||||
| Total noncurrent liabilities: | 1,169 | 658 | ||||||
| Total liabilities: | 3,199 | 1,091 | 219 | 168 | 121 | 52 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | (2,595) | (468) | (215) | (168) | (107) | (48) | ||
| Additional paid in capital | 3,093 | 3,088 | 3,072 | 3,067 | 3,062 | 3,062 | ||
| Accumulated deficit | (5,688) | (3,556) | (3,287) | (3,235) | (3,170) | (3,110) | ||
| Total stockholders' equity: | (2,595) | (468) | (215) | (168) | (107) | (48) | ||
| TOTAL LIABILITIES AND EQUITY: | 604 | 623 | 4 | 0 | 13 | 4 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 TTM | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 351 | 196 | 5 | ||||
| Cost of revenue (Cost of Goods and Services Sold) | (1,695) | (144) | (3) | ||||
| Gross profit: | (1,344) | 51 | 2 | ||||
| Operating expenses | (14,283) | (295) | (48) | (47) | (58) | (48) | |
| Other undisclosed operating loss | (0) | ||||||
| Operating loss: | (15,627) | (244) | (46) | (47) | (58) | (48) | |
| Nonoperating expense | (103) | (25) | (5) | (17) | (0) | ||
| Foreign currency transaction loss, before tax | (1) | ||||||
| Interest and debt expense | (98) | (20) | (5) | (4) | |||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (3) | 4 | |||||
| Loss from continuing operations before equity method investments, income taxes: | (15,831) | (289) | (56) | (64) | (59) | (48) | |
| Loss from equity method investments | (1) | ||||||
| Other undisclosed income from continuing operations before income taxes | 101 | 20 | 5 | ||||
| Loss from continuing operations before income taxes: | (15,730) | (269) | (51) | (65) | (59) | (48) | |
| Income tax expense | (1) | (1) | (1) | ||||
| Loss from continuing operations: | (15,730) | (269) | (52) | (66) | (59) | (48) | |
| Loss from discontinued operations | (919) | ||||||
| Loss before gain (loss) on sale of properties: | (15,730) | (269) | (52) | (66) | (59) | (967) | |
| Other undisclosed net income | 1 | ||||||
| Net loss available to common stockholders, diluted: | (15,730) | (269) | (52) | (65) | (59) | (967) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 TTM | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (15,730) | (269) | (52) | (65) | (59) | (967) | |
| Comprehensive loss, net of tax, attributable to parent: | (15,730) | (269) | (52) | (65) | (59) | (967) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.